Investigators from UCLA Health found using artificial intelligence to help map out the boundaries of cancerous prostate tissue can significantly reduce the risk of underestimating the extent of prostate cancer—an advancement that can help ensure an accurate diagnosis, precise treatment planning and effective surgical procedures.
Helio Genomics, an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, has released results from its latest clinical trial demonstrating the superior performance of their HelioLiver Dx test compared to ultrasound.Â
A pioneering phase I CAR T-cell therapy trial for the treatment of glioblastoma at City of Hope, demonstrates promising clinical activity against incurable brain tumors, according to research published in Nature Medicine.
A study led by researchers from the University of Arizona Cancer Center at UArizona Health Sciences identified a biological mechanism that could lead to more effective treatments for breast cancer that has metastasized to the brain. The work was published in Clinical and Translational Medicine.Â
While most cell types experience a functional decline after years of proliferation and replication, T cells can proliferate seemingly indefinitely and without detriment.Â
Nutcracker Therapeutics Inc., a biotechnology company focused on developing RNA therapies through its proprietary technology platform, presented a poster on NTX-472, its new preclinical drug candidate for B cell lymphoma, at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago.
Scientists at UC Davis Comprehensive Cancer and the UC Davis Department of Radiology have discovered a novel way to image the unique blood supply of the lungs. Their findings, published in the Journal of Nuclear Medicine, suggest the new method could help determine if lung cancer treatment is working.
Robotic liver surgery can be a safe outpatient procedure, according to a study published in the Journal of the American College of Surgeons. In fact, 8% of the patients sampled in the analysis were discharged to go home on the same day.
For nearly two decades, how kidney cancer becomes resistant to rapalog drugs has baffled the scientific community. Now, a study by researchers at UT Southwestern Medical Center’s Kidney Cancer Program sheds light.Â
Cosylab, a provider of control systems and software solutions for complex and precise machines, has entered into a collaboration with Mayo Clinic to advance cancer care in the United States and beyond.Â
